1. Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Etie Moghissi, MD, FACE, Allen B. King, MD, FACE 
The American Journal of Medicine 
Volume 127, Issue 10, Pages S3-S10 (October 2014)
DOI: /j.amjmed
Copyright © 2014 The Authors Terms and Conditions

2. Figure 1
Antihyperglycemic therapy in type 2 diabetes: general recommendations (ADA/EASD position statement). Reproduced with permission from Inzucchi et al.4 DPP-4-i = dipeptidyl peptidase-4 inhibitor; Fx = bone fracture; GLP-1-RA = glucagon-like peptide-1 receptor agonist; GI = gastrointestinal; HbA1c = glycated hemoglobin; HF = heart failure; SU = sulfonylurea; TZD = thiazolidinedione.
The American Journal of Medicine  , S3-S10DOI: ( /j.amjmed )
Copyright © 2014 The Authors Terms and Conditions

3. Figure 2
Sequential insulin strategies in type 2 diabetes (ADA/EASD position statement 2012).
Reproduced with permission from Inzucchi et al.4
The American Journal of Medicine  , S3-S10DOI: ( /j.amjmed )
Copyright © 2014 The Authors Terms and Conditions

4. Figure 3
Algorithm for adding/intensifying insulin (EASD Comprehensive Diabetes Management Algorithm 2013). Reproduced with permission from Garber et al.20 BG = blood glucose; DPP4-i = dipeptidyl peptidase-4 inhibitor; FBG = fasting blood glucose; GLP-1-RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated hemoglobin; NPH = neutral protamine Hagedorn; TDD = total daily dose; T2D = type 2 diabetes.
The American Journal of Medicine  , S3-S10DOI: ( /j.amjmed )
Copyright © 2014 The Authors Terms and Conditions